BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for DA Erlanson

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fragment-to-Lead Medicinal Chemistry Publications in 2015.EBI
Astex Pharmaceuticals
Fragment-based drug discovery.EBI
Sunesis Pharmaceuticals
Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.EBI
Sunesis Pharmaceuticals
Fragment-to-Lead Medicinal Chemistry Publications in 2022.EBI
Astex Pharmaceuticals
Fragment-to-Lead Medicinal Chemistry Publications in 2021.EBI
Astex Pharmaceuticals
Fragment-to-Lead Medicinal Chemistry Publications in 2020.EBI
Vrije Universiteit Amsterdam
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.EBI
Biogen
Fragment-to-Lead Medicinal Chemistry Publications in 2019.EBI
Novartis Institutes For Biomedical Research
Fragment-to-Lead Medicinal Chemistry Publications in 2017.EBI
Astex Pharmaceuticals
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.EBI
Biogen
Fragment-to-Lead Medicinal Chemistry Publications in 2018.EBI
Frontier Medicines
Discovery of EBI
Amgen
Fragment-to-Lead Medicinal Chemistry Publications in 2016.EBI
Astex Pharmaceuticals
Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indicationsBDB
University of Maryland, Baltimore
4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139BDB
Takeda Pharmaceutical
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.BDB
Universit�� Lille Nord De France
Design, synthesis, and anticonvulsant activity of some derivatives of xanthone with aminoalkanol moieties.BDB
Jagiellonian University Medical College
Methods of treating retroviral infections and related dosage regimesBDB
Chimerix